Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Levy

Showing results (231-240 of 571) with videos related to

Pageof 58
Sort By:
Multiple Sclerosis and Related Disorders|April 27, 2020
The COVID-19 pandemic and the use of MS disease-modifying therapiesGavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|July 8, 2022
EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapiesNatalia Drosu, Gavin Giovannoni, Jeanette Lechner-Scott, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|June 10, 2010
n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicityRobert A Rifkin, Edward T Maggio, Sonny Dike, et al.
Multiple Sclerosis and Related Disorders|July 21, 2019
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorderSantiago Pardo, Gavin Giovannoni, Christopher Hawkes, et al.
Multiple Sclerosis and Related Disorders|February 13, 2026
Tolebrutinib and the FDAGavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
JAMA Neurology|January 22, 2014
Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacyMaureen A Mealy, Dean M Wingerchuk, Jacqueline Palace, et al.
Multiple Sclerosis and Related Disorders|April 22, 2021
B cell therapy and the use of RNA-based COVID-19 vaccinesAnastasia Vishnevetsky, Chris Hawkes, Jeannette Lechner-Scott, et al.
Iscience|December 1, 2025
Synthetic cells by the numbersChana G Sokolik, Maya Bar-Dolev, Ron Milo, et al.
Multiple Sclerosis and Related Disorders|March 23, 2022
Implications of Low-Titer MOG AntibodiesMichael Levy, E Ann Yeh, Christopher H Hawkes, et al.
The Journal of Biological Chemistry|February 27, 2003
Mitochondrial regulation of synaptic plasticity in the hippocampusMichael Levy, Guido C Faas, Peter Saggau, et al.
Pageof 58

Showing results (231-240 of 571) with videos related to

Sort By:
Pageof 58
Multiple Sclerosis and Related Disorders|April 27, 2020
The COVID-19 pandemic and the use of MS disease-modifying therapiesGavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|July 8, 2022
EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapiesNatalia Drosu, Gavin Giovannoni, Jeanette Lechner-Scott, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|June 10, 2010
n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicityRobert A Rifkin, Edward T Maggio, Sonny Dike, et al.
Multiple Sclerosis and Related Disorders|July 21, 2019
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorderSantiago Pardo, Gavin Giovannoni, Christopher Hawkes, et al.
Multiple Sclerosis and Related Disorders|February 13, 2026
Tolebrutinib and the FDAGavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
JAMA Neurology|January 22, 2014
Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacyMaureen A Mealy, Dean M Wingerchuk, Jacqueline Palace, et al.
Multiple Sclerosis and Related Disorders|April 22, 2021
B cell therapy and the use of RNA-based COVID-19 vaccinesAnastasia Vishnevetsky, Chris Hawkes, Jeannette Lechner-Scott, et al.
Iscience|December 1, 2025
Synthetic cells by the numbersChana G Sokolik, Maya Bar-Dolev, Ron Milo, et al.
Multiple Sclerosis and Related Disorders|March 23, 2022
Implications of Low-Titer MOG AntibodiesMichael Levy, E Ann Yeh, Christopher H Hawkes, et al.
The Journal of Biological Chemistry|February 27, 2003
Mitochondrial regulation of synaptic plasticity in the hippocampusMichael Levy, Guido C Faas, Peter Saggau, et al.
Pageof 58